Hydrocortison Hoechst® .

Hydrocortison Hoechst® is a prescription oral medication that contains the corticosteroid hydrocortisone as its active ingredient. It is marketed in the European Union and supplied in tablet form, although the specific strength is not disclosed on the label. The product belongs to the glucocorticoid class and is used under medical supervision for conditions requiring anti‑inflammatory or immunosuppressive therapy. Physicians prescribe it according to individual patient needs and laboratory monitoring.

Hydrocortison Hoechst® is indicated for several medical conditions where replacement of cortisol or suppression of inflammation is required. It is commonly employed in endocrine, dermatologic, and allergic contexts under physician guidance.

- Primary adrenal insufficiency (Addison’s disease) requiring cortisol replacement. - Congenital adrenal hyperplasia with glucocorticoid deficiency. - Acute or chronic inflammatory disorders such as arthritis, ulcerative colitis, or asthma exacerbations. - Severe allergic reactions, including drug‑induced or contact dermatitis. - Autoimmune conditions where immunosuppression is needed, e.g., systemic lupus erythematosus.

Adverse reactions to Hydrocortison Hoechst® can vary in frequency and severity.

Common: - Increased appetite or weight gain. - Mild mood changes or insomnia. - Elevated blood glucose levels.

Serious: - Severe hypertension or fluid retention. - Osteoporosis with increased fracture risk. - Suppressed adrenal axis leading to adrenal crisis if stopped abruptly.

When prescribing or taking Hydrocortison Hoechst®, several safety considerations should be observed.

- Do not use in patients with systemic fungal infections without appropriate antifungal coverage. - Monitor blood pressure, glucose, and electrolytes regularly during therapy. - Taper the dose gradually when discontinuing to avoid adrenal insufficiency. - Use with caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Assess for history of psychiatric disorders, as glucocorticoids may exacerbate symptoms. - Avoid in patients with known hypersensitivity to hydrocortisone or excipients.

Hydrocortison Hoechst® may interact with other medicines, influencing its effectiveness or safety.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy. - Combined therapy with other systemic glucocorticoids can increase risk of systemic toxicity.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may raise risk of gastrointestinal bleeding. - Anticoagulants (warfarin) may have enhanced anticoagulant effect. - Vaccines containing live attenuated organisms may have reduced efficacy. - Diuretics may potentiate fluid‑retention effects.